Filing Details

Accession Number:
0001415889-23-004315
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-06 16:30:22
Reporting Period:
2023-03-02
Accepted Time:
2023-03-06 16:30:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650664 Editas Medicine Inc. EDIT Biological Products, (No Disgnostic Substances) (2836) 464097528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1755098 Michelle Robertson C/O Editas Medicine, Inc.
11 Hurley St.
Cambridge MA 02141
Evp, Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-02 31,500 $0.00 107,743 No 4 A Direct
Common Stock Disposition 2023-03-03 184 $8.89 107,559 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2023-03-02 94,500 $0.00 94,500 $8.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
94,500 2033-03-01 No 4 A Direct
Footnotes
  1. The common stock received by the Reporting person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
  2. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
  3. This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.